Featured Story

  • Roche's M&A party rages on with Kapa Biosystems deal

    Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.

FDA scolds Cepheid for manufacturing issues in Sweden

The FDA slapped Cepheid with a warning letter for violations at its European R&D and manufacturing site in Sweden, chastising the company for the way it went about producing its Xpert Norovirus diagnostic.

Sequenom strikes liquid biopsy research deal with UC San Diego Moores

Sequenom has already made waves with its noninvasive prenatal diagnostic, revealing earlier this year that its technology could uncover signs of cancer in pregnant women. Now, the company is moving forward with its new liquid biopsy test, teaming up with the UC San Diego Moores Cancer Center to use its tool to monitor cancer patients and match them with a suitable therapy. 

Veritas Genetics gets CE mark to conduct BRCA testing in Europe

Boston's Veritas Genetics received a CE mark to conduct BRCA gene testing for likelihood of inheriting breast and inheriting cancer in Europe.

LabCorp announces nationwide launch of its VistaSeq multigene cancer panel

LabCorp announced that its 27-gene VistaSeq Hereditary Cancer Panel to detect patients with increased risk of various cancers--including breast, ovarian, melanoma, pancreatic colorectal, endometrial, gastric and prostate cancer--is now available nationwide.  

Roche shops around for sequencing tech with Lumora buy

Roche has been hot on the trail of sequencing deals this past year, snatching up companies to build out its genomic analysis offerings. In its latest move, the company is buying sequencing products from molecular diagnostics firm Lumora to support its burgeoning portfolio.


From Our Sister Sites


Now that Amgen and the Regeneron/Sanofi team have scored pioneering approvals of two leading PCSK9 therapies, the race is already on to top the leaders with a new wave of even better drugs that can slash levels of bad cholesterol more efficiently. And Alnylam, alongside its partners at The Medicines Company, has staked out a claim to an RNAi treatment that could beat them all--some 5 years down the road.


While there were plenty of health startups among the more than 30 companies featured at the first ever White House Demo Day in August, only one could boast it's already making a splash in animal health: New York based Suneris. During the event, the company's founder, Joe Landolina, demonstrated Vetigel, an algae-derived product designed to stop traumatic bleeding in 10 seconds.